Skip to main content
ANTX
NASDAQ Life Sciences

AN2 Therapeutics Reports Q1 Results, Details Dilutive Financing, CEO Adopts 10b5-1 Plan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$4.782
Mkt Cap
$169.899M
52W Low
$1
52W High
$6.91
52W Position info
378% above low
Off High info
31% below high
Rel. Volume info
0.2× avg
Market data snapshot near publication time

ANTX has more than doubled off its 52-week low of $1 on light trading volume (0.2× avg).

Summary

AN2 Therapeutics reported a narrower Q1 net loss and increased cash reserves due to recent dilutive financing, while its CEO adopted a plan to sell 450,000 shares. The company also provided updates on its clinical pipeline and noted continued material weaknesses in internal controls.


Key Events · Financing and Capital Events · ANTX

  • Q1 Financials & Cash Burn

    Reported a Q1 2026 net loss of $10.0 million, a slight improvement from $10.6 million in Q1 2025. However, cash used in operating activities increased to $12.1 million from $10.6 million in the prior year period.

  • Increased Cash Position & Runway

    Cash, cash equivalents, and investments increased to $85.3 million as of March 31, 2026, up from $60.04 million at December 31, 2025. Management believes this provides sufficient funding for at least 12 months.

  • Details of Dilutive Private Placement

    The company finalized a $40.0 million gross private placement in March 2026, issuing 8,245,611 common shares at $2.85 per share and 5,789,493 pre-funded warrants at $2.84999 per warrant, resulting in $37.3 million net proceeds. This pricing represents a deep discount to the current market price.

  • New At-The-Market (ATM) Offering Program

    Confirmed the establishment of a new ATM equity offering program in April 2026, allowing the company to sell up to an aggregate of $80.0 million in common stock from time to time. This program introduces significant potential future dilution.


Analysis · ANTX · Life Sciences

This quarterly report provides detailed financial results and confirms significant capital-raising activities previously announced, including a deeply discounted private placement and a large At-The-Market (ATM) offering. While these financings extend the company's cash runway, they come at a substantial dilutive cost to existing shareholders. A new disclosure of the CEO adopting a 10b5-1 plan to sell a significant number of shares adds a negative signal. The company also continues to report material weaknesses in internal controls, which is a persistent concern. Positive updates on multiple clinical programs offer some counterbalance, indicating active development after a prior clinical setback.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ANTX was trading at $4.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $169.9M. The 52-week trading range was $1.00 to $6.91. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ANTX - Latest Insights

ANTX
Nov 09, 2026, 7:33 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.00
Real-time Price: $4.55 info
Change: +$0.550 (+14%) info
Market Cap: $172.644M info
ANTX
Nov 02, 2026, 7:00 AM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $4.54
Real-time Price: $4.55 info
Change: +$0.0100 (+0.22%) info
Market Cap: $172.644M info
ANTX
Aug 11, 2026, 4:09 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $5.87
Real-time Price: $4.55 info
Change: -$1.32 (-22%) info
Market Cap: $172.644M info
ANTX
Aug 11, 2026, 4:04 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $5.87
Real-time Price: $4.55 info
Change: -$1.32 (-22%) info
Market Cap: $172.644M info
ANTX
Aug 11, 2026, 4:01 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $5.87
Real-time Price: $4.55 info
Change: -$1.32 (-22%) info
Market Cap: $172.644M info